Veraxa Biotech AG

Stage 4 · Declining · week 17

As of Oct 22, 2026, Veraxa Biotech is in Stage 4, the downtrend phase, now in week 17 (since Jun 30, 2026). It closed at $1.03, 95.8% below its 52-week high and below its 200-day average, which is falling.

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. More about the company

$1.03

-7.21% today

$146M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VRXA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-09-30 → 2026-10-22

S? 42w

S2 46w

S4 16w

2024-09-302026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S2 46w → S3 1w → S2 2w → S3 1w → S4 16w current

Total tracked: 108 weeks across 6 stage runs.

VRXA among Biotechnology514th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…514	VRXAVeraxa Biotech AG	Stage 4 · wk 17	7	−25.9%

vs 52W High

-95.8%

$1.00 lo$24.79 hi

95.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 17

1w13w26w

Week 17, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-85.8%

200 DMA: $7.25 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.60x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-25.9%

-42.8%

-91.7%

YTD

-90.3%

-90.2%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 17 · Vol 0.60x

2026-10-21S4

Wk 16 · Vol 0.68x

2026-10-20S4

Wk 16 · Vol 0.44x

2026-10-19S4

Wk 16 · Vol 0.42x

2026-10-16S4

Wk 16 · Vol 0.44x

2026-10-15S4

Wk 16 · Vol 0.40x

2026-10-14S4

Wk 15 · Vol 0.22x

2026-10-13S4

Wk 15 · Vol 2.72x

2026-10-12S4

Wk 15 · Vol 0.57x

2026-10-09S4

Wk 15 · Vol 7.76x

2026-10-08S4

Wk 15 · Vol 0.89x

2026-10-07S4

Wk 14 · Vol 3.25x

Moving averages & range

50 DMA

$1.43

200 DMA

$7.25

52W High

$24.79

52W Low

$1.00

5D Low

$1.00

Resistance levels (recent highs)

20d High

$1.41

60d High

$1.99

120d High

$24.79

250d High

$24.79

Next resistance

+36.9%

to 20d High

ROE

-871.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -0.8

Veraxa Biotech: quick answers

What stage is Veraxa Biotech in?

As of Oct 22, 2026, Veraxa Biotech (VRXA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 30, 2026 and is in week 17. What the four stages mean

Is Veraxa Biotech in an uptrend?

No. Veraxa Biotech is in a Stage 4 downtrend. It trades 85.8% below its 200-day average, which is falling.

How far is Veraxa Biotech from its 52-week high?

Veraxa Biotech closed at $1.03 on Oct 22, 2026, 95.8% below its 52-week high of $24.79. Its 52-week low is $1.00.

How has Veraxa Biotech performed over the past year?

As of Oct 22, 2026, Veraxa Biotech is down 90.2% over the past year and down 90.3% so far in 2026.

Which sector and industry is Veraxa Biotech in?

Veraxa Biotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.